Proactive Investors - Run By Investors For Investors

Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer

The clinical trial will include two stages and outcomes will be released in June 2019.
Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer
The first single ascending dose will be conducted in 40 healthy subjects

Pharmaxis Ltd (ASX:PXS) has begun dosing of the first subject in its phase-one clinical trial of an anti-fibrotic Lysyl Oxidase (LOX) inhibitor, focused on treating cancer.

The program compound is an oral once-a-day drug that inhibits all members from the lysyl oxidase enzyme family.

The company successfully cleared pre-clinical safety and toxicity studies in the third quarter of 2018 and has shown significant reductions in in-vivo models of kidney and lung fibrosis, as well as myelofibrosis and pancreatic cancer.

New approach for stromal tumour treatment

Pharmaxis chief executive officer Gary Phillips said: “Moving a new drug into the clinic for the first time is always a significant milestone and this will be the fourth time we have accomplished this during the last 5 years.

“I’m delighted with the productivity of the Pharmaxis team and excited about the potential of this drug to bring a new approach to therapy for hard to treat stromal tumours like pancreatic cancer.

“Our current plan is that a successful phase 1 trial outcome would be the launch pad for a quick transition into cancer patients and to that end we are already in discussion with key leaders and working on potential trial designs.”

READ: Pharmaxis well-funded as potential partners assess its anti-fibrotic mechanisms

The double-blind placebo-controlled study consists of two stages.

The first single ascending dose will be conducted in 40 healthy subjects divided into five groups with each subject taking a single dose or placebo.

The second multiple ascending dose stage will be conducted in 16 healthy subjects and divided into two groups, with each group receiving a different dose or placebo for seven days.

 

 

READ: Pharmaxis LOXL2 program phase 2 ready after completion of 13-week toxicity studies

The company received reports on the 13-week toxicity studies in January 2019 which were conducted for each of its two Lysyl Oxidase Like 2 (LOXL2) inhibitors.

Both were drug compounds were tested at a range of doses in two species over the 13-week period to establish the No Observed Adverse Effect Level (NOAEL).

Doses that resulted in 85% or greater inhibition of the target enzyme in the phase 1 studies were below the human equivalent NOAEL doses and therefore an adequate safety margin to start phase 2 studies up to three months.

The Australian pharmaceutical research company is focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.Its product Bronchitol for cystic fibrosis is marketed in Europe, Russia and Australia and its product Aridol, for the assessment of asthma is sold in the US, Europe, Australia and Asia.

Its product Bronchitol for cystic fibrosis is marketed in Europe, Russia and Australia and its product Aridol, for the assessment of asthma is sold in the US, Europe, Australia and Asia.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use